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ABSTRACT
The stem–loop binding protein (SLBP) binds the
30 end of histone mRNA and is present both in
nucleus, and in the cytoplasm on the polyribosomes.
SLBP participates in the processing of the histone
pre-mRNA and in translation of the mature message.
Histone mRNAs are rapidly degraded when cells are
treated with inhibitors of DNA replication and are
stabilized by inhibitors of translation, resulting in
an increase in histone mRNA levels. Here, we show
that SLBP is a component of the histone messenger
ribonucleoprotein particle (mRNP). Histone mRNA
from polyribosomes is immunoprecipitated with
anti-SLBP. Most of the SLBP in cycloheximide-treated
cells is present on polyribosomes as a result of
continued synthesis and transport of the histone
mRNP to the cytoplasm. When cells are treated with
inhibitors of DNA replication, histone mRNAs are
rapidly degraded but SLBP levels remain constant
and SLBP is relocalized to the nucleus. SLBP remains
active both in RNA binding and histone pre-mRNA
processing when DNA replication is inhibited.
INTRODUCTION
The replication-dependent histone mRNAs in metazoans
are the only eukaryotic mRNAs that do not end in poly(A)
tails. Instead the replication-dependent histone mRNA’s end
in a highly conserved 26 nt sequence that contains a 16 nt
stem–loop (1,2). Replication-dependent histone genes also
lack introns; consequently, the only processing reaction
required for formation of a mature histone mRNA is cleavage
after the stem–loop to form the 30 end (2). Since histone
mRNAs lack a poly(A) tail, it is likely that the 30 end of histone
mRNAs and associated factors are important for their translation, much as the poly(A) tail, together with the poly(A) binding protein (PABP), plays an important role in the translation
of polyadenylated eukaryotic mRNAs (3–5). The 30 end of
histone mRNA is also important for its localization to polyribosomes (6) and mRNAs ending in the stem–loop are

translated with efficiencies comparable to polyadenylated
mRNAs (7). We have recently shown that the stem–loop binding protein (SLBP) stimulates translation of reporter mRNAs
ending in the stem–loop both in vivo and in vitro (8).
The levels of histone mRNA are 35-fold higher during
S phase than G1 phase (9) and are coupled to the rate of
DNA replication (10,11). Inhibition of DNA replication results
in the rapid degradation of the polyribosomal histone mRNA
(12). The 30 end of histone mRNA is the cis-acting element
responsible for this regulatory response (13). A 30 to 50 exonuclease associated with polyribosomes has been implicated in
the degradation of histone mRNA (14–17), consistent with a
role for the 30 end of histone mRNA in the regulation of
histone mRNA half-life.
A trans-acting factor, SLBP (also known as the hairpin
binding protein, HBP) that interacts with the stem–loop has
been identified in mammalian cells (18,19). SLBP is required
for efficient histone pre-mRNA processing (2,20), associating
with the histone pre-mRNA in the nucleus, and likely accompanies the histone mRNA to the cytoplasm as part of the
histone messenger ribonucleoprotein (mRNP) (21). SLBP is
also cell cycle regulated (22). As cells enter the S phase the
synthesis of SLBP is activated by increasing the translation
rate of the SLBP mRNA. SLBP is rapidly degraded at the end
of S phase as a result of its phosphorylation (22,23). Here, we
demonstrate that some of the polyribosomal histone mRNAs
are bound to SLBP. Histone mRNA is rapidly degraded when
cells in S phase are treated with inhibitors of DNA replication,
but SLBP is stable, and relocates to the nucleus.
MATERIALS AND METHODS
Cell culture
Mouse myeloma cells were cultured in DMEM with 10%
horse serum, 100 U/ml penicillin and 100 mg/ml streptomycin
(Life Technologies). Typically, cells were grown to a density
of 3 · 105 to 5 · 105 cells/ml prior to harvesting. For treatment
with DNA and protein synthesis inhibitors, a single culture
was divided and treated with the inhibitors of translation or
DNA synthesis for the time described in each experiment. The
following concentrations were used for drug treatments:
0.1 mM cycloheximide (CHX), 2 mM 5-fluorodeoxyuridine
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(FUdR), 5 mM hydroxyurea (HU) or 5 mg/ml aphidicolin
(Apd).
Preparation of nuclear extract and polyribosomes
Cells were fractionated as described previously (24). Briefly,
cells (from 1–6 l of suspension culture) were allowed to swell
in hypotonic buffer, lysed with a Dounce homogenizer and
nuclei pelleted by low-speed centrifugation (1000 g, 10 min).
Nuclear extracts were prepared from mouse myeloma cells
exactly as previously described (20,25). A synthetic histone
H2a-614 pre-mRNA was used for assaying histone pre-mRNA
processing as previously described (20).
Polyribosomes were prepared by first removing the mitochondria by centrifugation at 10 000 g for 10 min. The cytoplasm was then layered over a 1 M sucrose cushion and
centrifuged at 100 000 g for 4 h to pellet the polyribosomes.
Polyribosomes were suspended in 10 mM HEPES–KOH,
pH 7.9, 1.5 mM MgCl2, 20 mM KCl, 0.5 mM DTT, 0.75 mM
spermidine, 0.15 mM spermine by gentle homogenization and
stored at 80 C.
Measurement of SLBP synthesis rate
SLBP synthesis rate was determined essentially as described
previously (22). Cells were preincubated in DMEM, without
methionine and cysteine supplemented with 10% dialyzed
fetal bovine serum, for 1 h prior to labeling to deplete intracellular stores of methionine and cysteine. SLBP synthesis rate
in Chinese Hamster Ovary (CHO) cells treated with inhibitors
of DNA synthesis was measured by pulsing cells with 1 mCi of
[35S]methionine–cysteine for 15 min intervals after inhibition
of DNA synthesis with 5 mg/ml Apd (NEN Life Science Products, Boston, MA). Whole-cell extracts were incubated with
anti-SLBP and the SLBP–antibody complexes recovered by
binding to protein A agarose beads. The bound proteins were
eluted in SDS loading buffer and resolved by gel electrophoresis and detected by autoradiography (22).
Detection of phosphorylated SLBP
An aliquot of 2.5 · 106 mouse myeloma cells were grown in
100 mM culture dishes with 5 ml of phosphate-free media
supplemented with 10% dialyzed horse serum. Cells were
grown in phosphate-free media for 1 h prior to labeling to
deplete the intracellular stores of phosphate. Cells were then
labeled for 3 h with 1 mCi of [32P]orthophosphate (ICN) at
a concentration of 0.2 mCi/ml. Whole-cell lysates were
prepared by incubating cells in NP-40 lysis buffer (0.1%
NP-40, 50 mM Tris–HCl, pH 8.0, 150 mM NaCl, 50 mM
NaF, 1 mM DTT) for 10 min. Insoluble material was removed
by centrifugation at 13 000 g and the soluble supernatant used
for subsequent immunoprecipitations.
SLBP RNA binding activity
Mobility shift assays to detect SLBP binding were performed
using a 30 nt histone RNA stem–loop (25). The SLBP was
detected by western blotting using the anti-SLBP antibody as
described previously (18).
Antibody precipitation of polyribosomes
The SLBP antibody used for RNA precipitation was affinity
purified against the antigenic C-terminal peptide coupled to a

Sulfolink column (Pierce, Rockford, IL). Typically 10 mg of
peptide was coupled to the Sulfolink column and the antibody
purified from 2–5 ml of serum. Antibody was eluted from the
column, neutralized to pH 7.0 and stored in sodium azide.
All operations were performed at 4 C. Polyribosomes (5–
10 mg of polyribosomal RNA) were diluted into 100 ml of
NP-40 buffer [0.1% NP-40, 50 mM Tris–HCl, pH 7.5,
150 mM NaCl, 50 mM NaF, 1 mM DTT, 10 mM EDTA,
40 U RNAsin (Promega, Madison, WI)]. Lysates were precleared by incubation with 10–20 ml of protein A beads for
30 min to remove any non-specific binding material. Beads
were removed by sedimentation in a microcentrifuge at
4000 r.p.m. (1500 g) for 4 min. The supernatant was removed
and incubated for 1 h with the affinity-purified anti-SLBP
(0.1–0.2 mg) and then with 10 ml of protein A agarose
beads for an additional 1 h. The beads were recovered by
centrifugation at 2000 r.p.m. (400 g) for 2 min and the
complexes washed three times with the NP-40 lysis buffer.
RNA was prepared from both the supernatants and the pellets. The supernatant from the precipitation (100 ml) was
mixed with an equal volume of urea lysis buffer (ULB, 7 M
urea, 2% SDS, 0.35 M NaCl,10 mM EDTA, 10 mM Tris–HCl,
pH 7.5) and extracted with phenol–chloroform and the RNA
recovered by precipitation with ethanol. To prepare RNA from
the immunoprecipitates, the beads were suspended in 200 ml of
ULB and processed as above.
Histone mRNA levels in mouse RNA samples were measured by S1 nuclease mapping using the following probes. The
histone H3.2 mRNAs were mapped using the H3.2-614 gene
labeled at the SalI site and the H3.3 mRNAs were mapped
using the H3.3 gene labeled at the 50 end of the BglII site (26).
The H1b and H1c genes were mapped using the H1c gene
labeled at the NotI site (27). Actin mRNA was analyzed using
a ribonuclease protection assay.
Histone mRNA levels in HeLa cell mRNP precipitates were
measured by RT–PCR. Four micrograms of RNA from each
supernatant and an equivalent fraction of each precipitate
(typically one-tenth of the total precipitate) were reverse transcribed into cDNA with Superscript II (Invitrogen Life Technologies) primed with random hexamers according to the
manufacturer’s protocols. Each cDNA synthesis reaction
was purified using QIAquick PCR Purification Kit (Qiagen
Sciences, MD) and eluted with water in a volume of 30 ml.
Each PCR reaction was performed in a 25 ml reaction volume,
1.5 ml of purified cDNA and 5 pmol of each primer were
incubated in 10 mM KCl, 10 mM (NH4)2SO4, 2 mM
MgSO4, 0.1% Triton X-100, 2.5 U Taq DNA polymerase
(New England BioLabs, MA) for 28 cycles (92 C, 30 s;
60 C, 30 s; 72 C, 30 s). The primers for each gene were as
follows: HIST1H1A (AF531299.1, forward GGAGAAGAACAACAGCCGCAT, reverse TTGAGCTTGAAGGAACCCGAG, 104 bp amplicon); HIST1H2AB (AY131983.1, forward
ACAACAAGAAGACCCGCATCAT, reverse TATTAGGCAAAACGCCACCCT, 116 bp amplicon); HIST1H2BG
(AF531290.1, forward ACAAGCGCTCGACCATTACCT,
reverse TGGTGACAGCCTTGGTACCTTC, 107 bp amplicon);
HIST1H4B (AY128655.1, forward GGATAACATCCAAGGCATCACC, reverse CGCCACGAGTCTCCTCATAAAT, 100 bp amplicon); H3F3B (NM_005324.3, forward
TGGTTTTTCGCTCGTCGACT, reverse GGCCATTTTCTTTCACCCAAC, 102 bp amplicon); FOXM1 (NM_021953,
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forward GTGGCGATCTGCGAGATTTTG, reverse TCTTTCCCTGGTCCTGCAGAAG, 123 bp amplicon); CCNE1
(NM_001238.1, forward GGAAGAGGAAGGCAAACGTGA,
reverse TTATTGTCCCAAGGCTGGCTC, 108 bp amplicon).
PCR products were resolved on a 2% agarose gel in 0.5· TAE
and visualized by staining with ethidium bromide.
Sucrose gradient fractionation of polyribosomes
Mouse myeloma cells were lysed in hypotonic buffer and the
nuclei and mitochondria removed by centrifugation. The cytoplasm was adjusted to 0.1% NP-40, 0.1 M NaCl, 5 mM
Mg(OAc)2 and layered on a 15–40% sucrose gradient containing 0.1 M NaCl, 5 mM Mg(OAc)2, 10 mM Tris, pH 7.5.
Polyribosomes were fractionated by centrifugation at 39 000
r.p.m. for 2.5 h in an SW841 rotor. Aliquots of 0.5 ml were
collected and RNA was prepared from 0.3 ml of each aliquot.
RNA prepared from each fraction was analyzed by agarose gel
electrophoresis to identify the monoribosome peak (fractions 6
and 7). Protein was prepared from each fraction and analyzed
by SDS–gel electrophoresis followed by western blotting for
SLBP. SLBP binding was analyzed with a radiolabeled stem–
loop probe by native gel electrophoresis as described previously (28). Histone H2a mRNA levels were measured by
S1 nuclease mapping as described previously (11,26).
Immunostaining
HeLa cells stably expressing an hemagglutinin(HA)-tagged
SLBP (23) were plated onto coverslips at low density and
synchronized by a double thymidine block as described in
(22). S-phase cells (3 h after release from the thymidine
block) were treated with either HU or CHX for 1 h. Cells
were then fixed with 4% paraformaldehyde, washed with
phosphate-buffered saline and permeabilized with 0.5% Triton
X-100. Detection of the HA–SLBP was carried out using a
monoclonal a-HA antibody kindly provided by Dr Yue Xiong
at a dilution of 1:250 followed by incubation with a cy3 labeled
anti-mouse antibody (1:500, Jackson Immunoresearch). Nuclei
were counterstained with 4,6-diamidino-2-phenylindole
(DAPI) (0.1 mg/ml).
RESULTS
Histone mRNAs are rapidly (<5 min) processed and transported to the cytoplasm (29) where they are efficiently translated. The histone mRNA 30 end binds a protein, SLBP, which
associates with the histone pre-mRNA in the nucleus and is
necessary for histone pre-mRNA processing (20). SLBP also
stimulates translation of histone mRNA (8), suggesting that
it is associated with histone mRNA during at least the initial
round(s) of translation. Here, we show that histone mRNA is
co-precipitated with SLBP from polyribosomes, and have
determined the subcellular localization of SLBP and its fate
after degradation of histone mRNA.
Histone mRNAs are precipitated with anti-SLBP
To directly determine whether SLBP is associated with histone
mRNA on polyribosomes, we incubated isolated polyribosomes with anti-SLBP (in the presence of EDTA to dissociate
the polyribosomes), and recovered the SLBP–antibody complex with protein A agarose beads. RNA was prepared from
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the bound and unbound fractions and analyzed for the presence
of different mRNAs by nuclease protection assays. We performed the precipitation under a variety of conditions with
various detergents and for different amounts of time to determine the conditions for optimal precipitation of histone
mRNA with minimal background binding. Essentially similar
results were obtained using a variety of non-ionic detergents.
Using either 0.1% NP-40 or 0.1% Tween-20 we were able to
precipitate 20–30% of the histone mRNA present on polyribosomes with the affinity-purified anti-SLBP antibody
(Figure 1A, lanes 3 and 5).
There was a detectable difference in the length of the histone mRNA in the precipitated and non-precipitated fractions
(see Figure 1A, lanes 3–6). The histone mRNA precipitated
with anti-SLBP was similar in length to the mRNA formed
in the processing reaction. Most of the histone mRNA that
was in the supernatant was several nucleotides shorter, suggesting that it had been trimmed by exonucleases associated
with the polyribosomes (15,17). Since the histone mRNA in
the total polyribosomal RNA preparation was largely full
length (Figure 1A, lane 2), it is likely that the shortening of
the RNA occurred during the incubation with the antibody,
and/or subsequent washing procedures.
The precipitation of histone mRNA was specific for the antiSLBP. There were substantial amounts of histone H3.2 mRNA
present in the bound fraction only when anti-SLBP was used
(Figure 1B, middle panel, lane 5) but not when the antibody
was preincubated with the antigenic peptide (Figure 1B,
lane 6) or when the precipitation was performed with an
unrelated antibody (Figure 1B, lane 7), e.g. against Cullin-1
(30). Overall 20–30% of the histone mRNA was precipitated
by the anti-SLBP antibody depending on the experiment.
In order to further determine the specificity of the precipitation, we measured the levels of two different mRNAs that we
expected would not be precipitated by the anti-SLBP. There
was no precipitation of the histone H3.3 mRNA, an mRNA for
a replacement histone (Figure 1B, lane 5, upper panel), which
does not contain a histone stem–loop but, instead, ends in a
poly(A) tail (31), or of the abundant actin mRNA (Figure 1B,
lane 5, lower panel).
We also analyzed the immunoprecipitates for two histone
H1 mRNAs, H1c and H1b. These two mRNAs are both measured using the same probe in the S1 nuclease assay since their
sequences are nearly identical for a large portion of the coding
region (27). Both H1c and H1b mRNAs were precipitated by
the anti-SLBP antibody (Figure 1C, lane 5) but not by the
antibody preincubated with the antigenic peptide (Figure 1C,
lane 4), with preimmune serum (lane 6), or with antibodies to
the histone binding protein p48 or anti-CD3 antibodies (Figure
1C, lanes 2 and 3).
We also tested the ability of the anti-SLBP to precipitate the
histone mRNAs from the HeLa cell polyribosomes. The precipitated RNAs were analyzed for histone mRNAs and several
control mRNAs (histone H3.3, and two cell-cycle-regulated
mRNAs FOXM1 and CCNE1) using RT–PCR. We designed
primers to allow us to detect multiple members of the core
histone mRNA family (32) and histone H1a mRNA. All the
histone mRNAs were precipitated by SLBP and precipitation
was competed by the peptide antigen (Figure 1D), while the
other mRNAs were not precipitated by anti-SLBP. Since all of
the replication-dependent histone mRNAs that we have tested
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Figure 1. SLBP is bound to histone mRNAs in the cell. (A) Polyribosomes isolated from mouse myeloma cells were suspended in buffer containing 10 mM EDTA as
described in Materials and Methods. a-SLBP was added in the presence of either 0.1% Tween-20 (lanes 3 and 4) or 0.1% NP-40 (lanes 5 and 6). RNA was prepared
from the immunoprecipitates (lanes 3 and 5) and from the supernatant fraction (lanes 4 and 6) and analyzed by S1 nuclease mapping using the histone H3-614 gene as a
probe. RNA prepared from polyribosomes was analyzed in lane 2 and yeast tRNA in lane 1. There is a small size differences (2–4 nt) observed between the total RNA
(lane 2) and the immunoprecipitated mRNA compared with the RNA that did not immunoprecipitate. The final lane is pUC18 digested with HpaII.
(B) Immunoprecipitations were performed from mouse myeloma polyribosomes with preimmune serum (pi) (lanes 4 and 9), a-SLBP (lanes 5 and 10),
a-SLBP preincubated with 1 mg of antigenic peptide (lanes 6 and 11) or with an unrelated antibody, a-CUL (lanes 7 and 12). RNA was prepared from both
supernatants and precipitates and analyzed for the polyadenylated H3.3 histone mRNA (upper panel) or the replication-dependent H3.2-614 mRNA (middle panel) by
S1 nuclease mapping. The same RNA samples were analyzed for the mouse b-actin mRNA using a ribonuclease protection assay (lower panel). Analysis of total RNA
or polyribomosal RNA are shown for H3.3 and H3.2 histone mRNAs but not for actin (lanes 1 and 2). A diagram of the S1 nuclease assay is shown below the figure.
(C) Immunoprecipitations were performed with preimmune serum (pi) (lanes 6 and 12), a-SLBP (lanes 5 and 11), a-SLBP with antigenic peptide (lanes 4 and 10) or
with the unrelated antibodies a-p48 and a-Cdk4 (lanes 2 and 3, and 8 and 9). RNA was prepared and analyzed by S1 nuclease mapping with the mouse H1c gene
which maps both the H1c and H1b mRNAs (27). S1 nuclease mapping of total mRNA from the same cells is shown (lane 1). Lanes 7 and 13 shows polyribosomes
incubated in buffer and then treated with protein A beads. Lane 14 is marker pUC18 digested with HpaII. A diagram of the S1 nuclease assay is shown below the
figure. (D) Immunoprecipitations were performed from polyribosomes isolated from HeLa cells with either no antibody (lanes 3 and 6), a-SLBP (lanes 2 and 5) or
a-SLPB with antigenic peptide (lanes 1 and 4). RNA was prepared and analyzed by RT–PCR with primers specific to H1a (HIST1H1A), H2a (HIST1H2AB), H2b
(HIST1H2BG) and H4 (HIST1H4B). The same RNA samples were assayed for the presence of the polyadenylated histone H3.3 mRNA (H3F3B) and two additional
cell-cycle-regulated mRNAs, FOXM1 and CCNE1 (62). PCR products were detected by ultraviolet (UV) illumination of ethidium bromide stained 2% agarose gels.

were precipitated by the anti-SLBP it is likely that SLBP is
bound to this class of messages on the polyribosomes, which
comprise more than 60 different mRNAs (32).
CHX treatment alters the subcellular localization of SLBP
When cells are fractionated into nuclear, cytosolic and polyribosomal fractions, >90% of the histone mRNA is present
in the polyribosomal fraction (6,33). We determined the

distribution of SLBP by western blotting and immunostaining.
When cells were fractionated biochemically, SLBP was found
in all subcellular fractions with much of the protein in the
polyribosomal fraction, as reported in (24) (Figure 2A,
lanes 3 and 4). As expected from its role in histone premRNA processing, significant amounts of SLBP were also
found in the nuclear fraction (Figure 2A, lanes 1 and 2).
There were also small amounts of SLBP found in the cytosolic
fraction (Figure 2A, lanes 5 and 6).
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Figure 2. Effect of protein synthesis inhibitors on SLBP modification and
localization (A) Mouse myeloma cells were grown normally (lanes 1–6) or
treated with 0.1 mM CHX for 1 h (lanes 7–12). Both cultures were fractionated
in parallel into nuclear extract (lanes 1, 2, 7, 8), polyribosomes (lanes 3, 4, 9, 10)
or post-polyribosomal supernatant (S130, lanes 5, 6, 11, 12). The right hand
panel is a longer exposure of the CHX fractionation (lanes 7–12). Extracts from
equivalent amounts of cells were analyzed by gel electrophoresis and the SLBP
detected by western blotting. There was some proteolysis of SLBP resulting in
removal of 10 kDa from the N-terminus (18). Aliquots of the fractions in evennumbered lane were treated with protein phosphatase prior to electrophoresis.
The position of unmodified SLBP and the proteolytic product are indicated by
the arrows. (B) Mouse myeloma cells were labeled with H3[32PO4] and left
untreated (lanes 1 and 3), treated with CHX for 2 h (lane 2) or treated with
the DNA synthesis inhibitor FudR for 1 h (lane 4). Total cell lysates were
prepared and the SLBP immunoprecipitated and resolved by SDS-PAGE.
Phosphorylated SLBP was detected by autoradiography. The position of
unmodified SLBP and the proteolytic product are indicated by the arrows.
(C) The nuclear, polyribosomal and S130 extracts from equivalent amounts
of mouse myeloma cells [same extracts as in panel (A)] were assayed by
mobility shift assay using a radiolabeled stem–loop RNA as a probe (40).
The stem–loop/RNA complex [(C) arrow] was resolved by native polyacrylamide gel electrophoresis.

Treatment of cells with inhibitors of protein synthesis
results in an increase in histone mRNA concentrations
(12,34). Blocking translation with CHX, which inhibits the
translocation step in protein synthesis, results in stabilization
of histone mRNA on polyribosomes and a 2- to 3-fold increase
in the steady-state amount of histone mRNA (12,34,35). When
cells are treated with CHX for 1 h and then fractionated,
histone mRNA was associated with ribosomes, as was the
great majority of the SLBP (Figure 2A, lanes 9 and 10).
There was a decrease in both the amount of nuclear SLBP
and cytosolic SLBP and a concomitant increase in the
amount of SLBP associated with polyribosomes (Figure 2A,
lanes 7–12). Since protein synthesis has been inhibited, the
change in the subcellular distribution of SLBP must reflect a
redistribution of pre-existing SLBP.
Histone gene transcription and processing continues when
cells are treated with CHX (12), utilizing the SLBP in the
nucleus for processing. Cytoplasmic histone mRNAs are stabilized, resulting in an increase in histone mRNA levels during
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CHX treatment. Ultimately, the majority of SLBP
accumulates in the cytoplasm associated with polyribosomes
in CHX-treated cells.
Although there was no significant change in the overall
amount of SLBP, treatment with CHX results in a lower
mobility of SLBP on SDS–polyacrylamide gels (Figure 2A,
lanes 7–12). This is a result of phosphorylation, since treatment of the samples with calf intestinal phosphatase resulted in
a shift in mobility back to the original mobility. There was no
shift in mobility of the SLBP in the samples from control cells
(Figure 2A, lanes 1–6).
To further confirm that SLBP is phosphorylated, we incubated cells with 32PO4 and isolated the SLBP by immunoprecipitation. Note that the SLBP in control cells is
phosphorylated since the SLBP is also labeled with 32PO4
in control cells, but this phosphorylation does not alter the
mobility of the protein (Figure 2A, lanes 1–6 and Figure 2B,
lane 1). The mobility of the phosphorylated SLBP is lower in
CHX-treated cells (Figure 2B, lane 2) but not in FUdR-treated
cells (Figure 2B, lanes 3 and 4) suggesting that SLBP is
hyperphosphorylated in CHX-treated cells. We assayed the
RNA binding activity of SLBP in the subcellular fractions
using a mobility shift assay. There was reduced binding
activity of SLBP in the nuclear and cytosolic fractions of
CHX-treated cells (Figure 2C), consistent with the results
of western blotting.
We also determined the localization of SLBP by immunofluorescence in a cell line expressing HA-tagged SLBP. These
cells express similar amounts of HA-tagged SLBP as
endogenous SLBP and the HA–SLBP is regulated in parallel
with the endogenous SLBP (23). The HA–SLBP was detected
by immunostaining with the anti-HA antibody. We analyzed
S-phase cells (3 h after release from a double thymidine block)
all of which express SLBP and histone mRNA. SLBP is present in both the nucleus and cytoplasm of S-phase cells
(Figure 3, left 2 columns). When cells are treated with
CHX, SLBP redistributes to the cytoplasm (Figure 3, middle
two columns), in agreement with the cell fractionation results.
SLBP levels do not change when histone mRNA
is degraded
Histone mRNAs are rapidly degraded when cells are treated
with inhibitors of DNA replication (11,12) and at the end of the
S phase (9,22). SLBP expression is tightly regulated during the
cell cycle, accumulating at about the same time as histone
mRNA and being rapidly degraded at the end of S phase at
about the same time as the histone mRNA is degraded (22,23).
Given the role of the 30 end of histone mRNA in the coordinate
regulation of histone mRNA levels during the cell cycle (9,36–
38), and in regulating histone mRNA degradation (13), we
asked whether there were changes in SLBP as a result of
treatments that altered histone mRNA metabolism.
After treating CHO cells for 45 min with three different
inhibitors of DNA replication (HU, Apd and FUdR), there was
at least a 20-fold reduction in histone mRNA levels (Figure 4A,
bottom). However, there was no decrease, but rather a slight
increase (2-fold) in total cellular SLBP with all three inhibitors (Figure 4A, top). SLBP was resolved into two forms by
gel electrophoresis, with the minor, slower migrating form
being phosphorylated. There was no change in the ratio of
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Figure 3. Localization of SLBP in cells treated with CHX or HU. HeLa cells expressing HA–SLBP were synchronized by double thymidine block. The cells were
released into S phase for 3 h. Separate cultures were treated for 1 h with CHX (middle two panels) or HU (right two panels). Untreated cells in S phase are shown in the
left two panels. Cells were fixed and the HA–SLBP detected by immunofluorescence (top panels) and DNA detected with DAPI (bottom panels) as described in
Materials and Methods.

phosphorylated and unphosphorylated forms of SLBP when
DNA replication was inhibited, consistent with the results of
32
PO4 labeling (Figure 2B). Thus SLBP is not degraded or
detectably modified when histone mRNA is degraded. These
results demonstrate that degradation of SLBP does not
accompany histone mRNA degradation when DNA synthesis
is inhibited.
Since the translation of SLBP mRNA is regulated during the
cell cycle (22), we also examined whether inhibition of DNA
replication affected the rate of SLBP synthesis in CHO cells.
The synthesis rate of the SLBP was determined at various
times after treatment with Apd by pulse labeling with
[35S]methionine for 15 min beginning at the indicated time
followed by immunoprecipitation of SLBP. The 0 h time point
represents cells that have not been treated with Apd. The
synthesis rate of SLBP increases 2-fold when cells are
treated with inhibitors of DNA replication (Figure 4B, lanes
3–5). Analysis of the SLBP mRNA levels shows a similar
small increase (data not shown) when cells are treated with
inhibitors of DNA replication. Thus, there is clearly not a
decrease in the synthesis of SLBP or rapid degradation of
SLBP when DNA synthesis is inhibited, in contrast to the
rapid disappearance of SLBP at the end of S phase (22).
SLBP returns to the nucleus after inhibition of DNA
replication

Figure 4. SLBP levels are not decreased when histone mRNA is degraded. (A)
CHO cells were treated with HU, Apd or FUdR for 1 h. Lysates and RNA were
prepared and analyzed for SLBP by western blotting (top) or histone H3 mRNA
by S1 nuclease mapping (bottom). The slower migrating band represents a small
amount of phosphorylated SLBP. (B) CHO cells were pulse labeled with
[35S]methionine for 15 min, at the time periods indicated on the graph at
the right. Apd was added to the cells at 0 min and then [35S]methionine
added at 15, 30 or 60 min. Equal amounts of cell lysate were precipitated
with anti-SLBP and the immunoprecipitates analyzed by gel electrophoresis
(left); the position of SLBP is indicated by the arrow. In lane 1, the antibody was
incubated with the antigenic peptide prior to immunoprecipitation. Above each
lane the time in minutes after Apd treatment is indicated. The 0 h points were not
treated with Apd (lanes 1 and 2). (C) Nuclear extracts were prepared from
exponentially growing mouse myeloma cells (lanes 1 and 3) or mouse myeloma
cells treated with FUdR (lane 2) or HU (lane 4) for 1 h. A synthetic radiolabeled
320 nt histone H2a pre-mRNA was incubated in the extract for 30 min, the RNA
purified, analyzed by gel electrophoresis and the RNA products detected by
autoradiography (20). The position of the substrate pre-mRNA and the 266 nt
processed mRNA are indicated.

When cells are treated with inhibitors of DNA replication and
histone mRNA is rapidly degraded, there is no decrease in
the amount of SLBP. To determine whether there was a
redistribution of SLBP when histone mRNAs were degraded
as a result of inhibition of DNA replication, we treated the
S-phase cells expressing the HA–SLBP with HU and then
analyzed the distribution by immunofluoresence with the
anti-HA antibody. When DNA replication was inhibited and
histone mRNA degraded, we observed a relocalization of
SLBP to the nucleus (Figure 3, right panels).
Extracts from cells treated with DNA synthesis
inhibitors are active in histone pre-mRNA processing
Treatment of cells with inhibitors of DNA replication results in
a rapid decrease in histone mRNA levels, with a much smaller
decrease in the rate of histone gene transcription (11,12). To
determine whether there was an effect on histone pre-mRNA
processing in cells treated with inhibitors of DNA replication,
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nuclear extracts were prepared from control cells and cells
treated with HU or FUdR. Both inhibitors result in a rapid
reduction in histone mRNA levels (Figure 4A). However,
extracts prepared from either FUdR- or HU-treated cells
processed synthetic histone pre-mRNA at least as well as
extracts prepared from control cells (Figure 4C). Thus there
is no difference in histone pre-mRNA processing in nuclear
extracts prepared from growing cells or cells treated with
inhibitors of DNA replication.
SLBP sediments with histone mRNA on small
polyribosomes
To obtain additional evidence that SLBP was associated with
histone mRNA on polyribosomes, we prepared cytosolic fractions from exponentially growing mouse myeloma cells and
fractionated them on 10–40% sucrose gradients to resolve the
polyribosomes. We analyzed polyribosome gradients from
control cells (Figure 5), cells treated with CHX (Figure 6),
and cells treated with HU (not shown, Supplementary Figure A).
After fractionation, the presence of histone mRNA was determined by an S1 nuclease protection assay, SLBP levels by
western blotting, SLBP binding activity by mobility shift assay
and the ribosomal RNA in each fraction by ethidium bromide
staining on an agarose gel.
Since histone mRNAs are small (coding region only 400 nt,
total length 500 nt) they are associated with small polyribosomes (Figure 5A). Under these conditions the mRNAs for
larger mRNAs such as GAPDH subunits (>1200 nt encoding a
30–40 kDa protein) are concentrated near the bottom of the
gradient (22). In the presence of CHX, histone mRNAs are
stabilized and are resistant to degradation by HU (12,39).
There is continued production of histone mRNA in the presence of CHX, resulting in an increase in histone mRNA levels
(12,34). Since CHX blocks the elongation of the polypeptide
chain, mRNAs synthesized and recruited for translation after
addition of CHX are associated with monoribosomes, resulting
in a shift in the overall population of histone mRNA toward the
top of the gradient (Figure 6A).
We analyzed each fraction for the presence of SLBP by
western blotting. In exponentially growing cells, much of
the SLBP was not tightly associated with polyribosomes
but remained at the top of the gradient (Figure 5B). There
was a peak of SLBP present in fractions 6–11, which include
the monoribosomes and small polyribosomes (Figure 5B).
There was clearly less SLBP associated with the larger polyribosomes that contained the largest amounts of histone
mRNA (Figure 5B, lanes 10–12). In cells treated with HU,
all of the cytoplasmic SLBP remained at the top of the gradient
(data not shown, Supplementary Figure A), and there was very
little histone mRNA in any of the fractions, demonstrating that
the observed association with ribosomes is dependent on the
presence of histone mRNA.
In CHX-treated cells, a much larger fraction of the total
SLBP in the cytosolic fraction was associated with polyribosomes, and there was a clear peak of SLBP in fractions 6–8
(Figure 6B). There was also a much larger proportion of the
total histone mRNA associated with fractions 6–8, the positions of monosomes, in CHX-treated cells (Figure 6A). Since
CHX blocks elongation of translation but not initiation, we
anticipate that histone mRNAs synthesized in the presence of

Figure 5. Association of SLBP with polyribosomes. Cytoplasmic lysate
prepared from exponentially growing HeLa cells was fractionated by
sucrose gradient centrifugation as described in Materials and Methods. The
fraction numbers from the sucrose gradients are indicated above each lane; PE is
the sucrose gradient pellet. The monoribosome peak (fractions 6 and 7 in each
panel) was identified by ethidium bromide staining of total RNA. (A) Total
RNA isolated from each fraction was analyzed for histone H2a mRNA by S1
nuclease mapping. Lane 1, marker (pUC18 digested with HpaII); lane 2, 10 mg
of yeast tRNA; lane 3, is analysis of 5 mg of RNA from the cytoplasmic extract;
lanes 4–18, sucrose gradient fractions. (B) An aliquot of each fraction sample
was analyzed by western blotting for SLBP. Lane 1, 10 mg of cytoplasmic
extract; lanes 2–16, sucrose gradient fractions. (C) An aliquot of each fraction
was analyzed for RNA binding activity with a mobility shift assay using the
radiolabeled stem–loop RNA as a probe. Lane 1, probe; lane 2, nuclear extract;
lane 3, cytoplasmic extract; lane 4, in vitro-translated SLBP; Lanes 5–19,
sucrose gradient fractions. (D) An aliquot of each fraction was analyzed by
agarose gel electrophoresis and the RNAs detected by ethidium bromide
staining. Lane 1, RNA from cytoplasmic extract; lanes 2–16: sucrose
gradient fractions 1-14 and the pellet (PE).

CHX would associate with only one ribosome. These newly
synthesized mRNAs are associated with SLBP when they are
associated with monoribosomes consistent with a role for
SLBP in the initiation of translation (8).
Importantly, the SLBP which co-fractionated with histone
mRNA in CHX-treated cells was unable to bind with an exogenously added stem–loop RNA, consistent with the interpretation that it is bound to the histone mRNA in the initial rounds
of translation (Figure 6B, fractions 8–10). In contrast, the
SLBP at the top of the gradient, which did not co-fractionate
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Figure 6. SLBP is associated with histone mRNA on ribosomes from CHXtreated cells. Cytoplasmic lysate prepared from HeLa cells treated with CHX
for 45 min were fractionated by sucrose gradient centrifugation. The fraction
numbers from the sucrose gradients are indicated above each lane; PE is the
sucrose gradient pellet. Fractions 6 and 7 contain the monoribosome peak as
determined by ethidium bromide staining to total RNA. (A) Total RNA isolated
from each fraction was analyzed for histone H2a mRNA by S1 nuclease
mapping. Lane 1, marker (pUC18 digested with HpaII); lane 2, 10 mg of
yeast tRNA; lane 3, 5 mg of RNA from the cytoplasmic extract; lanes 4–18,
sucrose gradient fractions. (B) Protein from each fraction was analyzed by
western blotting for SLBP. Lane 1, 10 mg of cytoplasmic extract; lanes
2–16, sucrose gradient fractions; PE, sucrose gradient pellet. (C) Each
fraction was analyzed for RNA binding activity by a mobility shift assay
using the radiolabeled stem–loop RNA probe. Lane 1, probe; lane 2, nuclear
extract; lane 3, cytoplasmic extract; lane 4, in vitro translated SLBP; lanes 5–19,
sucrose gradient fractions. (D) An aliquot of each fraction was analyzed by
agarose gel electrophoresis and the RNAs detected by ethidium bromide
staining. Lanes 1–15, sucrose gradient fractions 1–14 and the pellet (PE).

with histone mRNA, bound to the stem–loop very efficiently
(Figures 5C and 6C, fractions 1–3). We have previously shown
that under conditions used for the mobility shift assay, once
SLBP is bound to the stem–loop, it is not readily exchanged
onto another stem–loop RNA (40). Therefore, we interpret
these results to indicate that the SLBP tightly associated
with ribosomes is in a stable complex with histone mRNA
and not available for binding to the exogenously added probe,
consistent with SLBP being bound to histone mRNA as a
component of the mRNP.

The proteins that associate with pre-mRNAs in the nucleus are
critical factors for the regulation of mRNA processing and
transport to the cytoplasm. The regulation of mRNA stability
and translation is also mediated by proteins in the cytoplasmic
mRNPs, many of which may become associated with the
mRNA during the initial pre-mRNA processing steps in
the nucleus.
Polyadenylated mRNAs exist as an mRNP with the PABP
bound to their 30 ends. PABP is not required for pre-mRNA
processing but only binds to the mature mRNA at the time the
RNA enters the cytoplasm (41), replacing PAB2, which is
involved in polyadenylation (42). PABP stimulates initiation
of translation of an mRNA by interaction with the eIF4F cap
binding complex (eIF4G, eIF4E and eIF3) through interactions
with the N-terminal portion of eIF4G (43,44). These interactions effectively circularize the mRNA allowing the 30 end to
affect events at the 50 end of the message. Degradation of
polyadenylated mRNAs is initiated by deadenylation of the
mRNA, breaking the interaction between the 50 and 30 ends
of the mRNA.
There are proteins bound to the 30 -untranslated region
0
(3 -UTR) of many mRNAs. These include protein complexes
which stabilize the globin (45,46) and collagen (47) mRNAs,
as well as proteins that bind to AU-rich sequences and either
stabilize (48–51) or destabilize (52,53) the mRNA. The rev
protein binds to the 30 -UTR of full-length retroviral mRNAs
(which synthesize gag and gag/pol) and is required for export
of these mRNAs to the cytoplasm and remains associated with
the mRNA in the cytoplasm (54,55). These and/or other proteins bound to the 30 -UTR often participate in regulation of
translation of the mRNA (48).
There are also proteins that associate with the coding region
of the mRNA. Some of these bind during splicing and remain
associated with the mRNA possibly marking it for export into
the cytoplasm (56,57), and others affect the stability of the
mRNA (58,59). It is not known when these latter proteins
associate with the mRNA, but many of them are present
both in the cytoplasm and in the nucleus, and it is likely
that they associate with the mRNA during biosynthesis in
the nucleus or export into the cytoplasm.
During histone pre-mRNA processing in the nucleus, SLBP
becomes associated with the mature message and the data
presented here suggests that it accompanies the mature
message to the cytoplasm. S-phase cells, which have large
amounts of histone mRNA, contain SLBP in both the nucleus
and the cytoplasm (Figure 3). When DNA synthesis is inhibited and histone mRNAs are degraded, SLBP is not degraded,
but relocates to the nucleus. This result suggests that the SLBP
present in the cytoplasm is bound to histone mRNA, and this
interpretation is supported by the precipitation of histone
mRNAs with anti-SLBP (Figure 1).
SLBP has been shown to participate in translation initiation
(8) in the cytoplasm consistent with its association with histone mRNA on ribosomes. We find that SLBP is tightly associated with the histone mRNPs immediately after initiation
of translation, as evidenced by the association of the histone
mRNA synthesized in the presence of CHX with SLBP on
monoribosomes. In CHX-treated cells, there is a substantial
increase in the amount of SLBP associated with ribosomes; the
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bulk of this SLBP is associated with monoribosomes, coincident with the location of histone mRNAs synthesized in the
presence of CHX. SLBP is not associated with histone mRNPs
with multiple ribosomes for reasons that we do not understand.
Our data support the hypothesis that SLBP is tightly bound
during the initial round of translation and is less tightly associated with or is lost from the mRNP after several rounds
of translation.
In addition to a role in histone mRNA translation, it is likely
that SLBP plays a role in regulating histone mRNA degradation, as PABP does for polyadenylated mRNAs (60). The
initial step in histone mRNA degradation is likely to be trimming by an exonuclease starting from the 30 end of the mRNA
(14,17,61); consistent with this hypothesis, SLBP protects
histone mRNA from degradation by a purified 30 –50 exonuclease in vitro (17). Rapid degradation of histone mRNA in
response to inhibition of DNA synthesis occurs without any
reduction in SLBP levels. We have never observed any free
SLBP that was not capable of binding to the stem–loop. Indeed
depletion of either whole-cell (23) or nuclear extracts (20) with
a biotinylated stem–loop RNA removes all the SLBP as analyzed by western blotting. Thus, if there is a form of SLBP that
cannot bind RNA it must only exist transiently. It is possible
that the SLBP/RNA complex could be cleaved off the mRNA
by an endonucleolytic cleavage. Alternatively, the SLBP may
be displaced by modification of the SLBP resulting in recruitment or activation of an exonuclease.
SUPPLEMENTARY MATERIAL
Supplementary Material is available at NAR Online.
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